Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Iambic Therapeutics, Inc
Beijing Biotech
Amgen
National Institutes of Health Clinical Center (CC)
Blokhin's Russian Cancer Research Center
Blokhin's Russian Cancer Research Center
Neonc Technologies, Inc.
Essen Biotech
xCures
Swansea Bay University Health Board
University of Nebraska
Adela, Inc
Var2 Pharmaceuticals
Novartis
Mayo Clinic
Cancer Research UK
Merck Sharp & Dohme LLC
Massive Bio, Inc.
AVM Biotechnology Inc
LigaChem Biosciences, Inc.
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
Telix Pharmaceuticals (Innovations) Pty Limited
PharmaMar
Apollomics Inc.
Columbia University
Tempus AI
Stanford University
Universidade Federal de Pernambuco
Aminex Therapeutics, Inc.
Taproot Health
Washington University School of Medicine
NGM Biopharmaceuticals, Inc
University of Florida
Quadriga Biosciences, Inc.
Hospices Civils de Lyon
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Shenzhen BinDeBio Ltd.
Novartis
SpeciCare
National Institutes of Health Clinical Center (CC)
Southwest Hospital, China
Shenzhen BinDeBio Ltd.
Icahn School of Medicine at Mount Sinai
Swiss Cancer Institute
CureOne
Stanford University
Roswell Park Cancer Institute
M.D. Anderson Cancer Center